摘要
目的探析胸腺肽联合抗生素治疗老年慢性阻塞性肺疾病急性加重(AECOPD)的疗效及安全性。方法方便选取2013年6月—2015年3月该院收治的80例AECOPD老年患者进行分组研究,按照1:1比例分为参照组(n=40,予以常规治疗)和试验组(n=40,予以胸腺肽联合抗生素治疗),比较2组治疗总有效率和不良反应情况。结果 2组患者治疗期间均未出现明显不良反应,身体状况良好,且试验组治疗总有效率92.5%优于参照组65.0%,组间差异有统计学意义(P<0.05)。结论胸腺肽联合抗生素治疗老年慢性阻塞性肺疾病急性加重的疗效确切,安全可靠,值得使用和积极推广。
Objective To observe the Thymosin antibiotic treatment in elderly patients with chronic obstructive pulmonary disease （AECOPD） efficacy and safety. Methods Convenient selection selected June 2013— March 2015 in our hospital 80 cases of elderly patients with AECOPD group study. According to the 1： 1 ratio divided the patients into reference group （n=40, treated with routine therapy） and experimental group （n = 40 treated with thymosin antibiotics）, compared the total ef-fective rate and adverse reactions between the two groups. Results There was no significant adverse reactions during the patient treatment of the two groups, all in good physical condition. And the total effective rate of the test group is 92.5%, better than the reference group 65.0%,there is significant differences between the groups （P〈0.05）.Conclusion Thymosin antibiotic treatment in elderly patients with chronic obstructive pulmonary disease exacerbations effective, safe, reliable, worth using and actively promoting.
出处
《中外医疗》
2016年第23期139-140,共2页
China & Foreign Medical Treatment
关键词
慢性阻塞性肺疾病
抗生素
胸腺肽
Chronic obstructive pulmonary disease
Antibiotic
Thymosin
